表紙:高薬理活性原薬(HPAPI)の市場動向・市場シェア・市場規模予測(2021年~2028年):製品(合成、バイオテクノロジー)、メーカータイプ(社内、アウトソーシング)、薬剤タイプ、用途、地域別
市場調査レポート
商品コード
1030920

高薬理活性原薬(HPAPI)の市場動向・市場シェア・市場規模予測(2021年~2028年):製品(合成、バイオテクノロジー)、メーカータイプ(社内、アウトソーシング)、薬剤タイプ、用途、地域別

High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product (Synthetic, Biotech), By Manufacturer Type (In-house, Outsourced), By Drug Type, By Application, By Region, And Segment Forecasts, 2021 - 2028

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 140 Pages | 納期: 2-10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
高薬理活性原薬(HPAPI)の市場動向・市場シェア・市場規模予測(2021年~2028年):製品(合成、バイオテクノロジー)、メーカータイプ(社内、アウトソーシング)、薬剤タイプ、用途、地域別
出版日: 2021年09月28日
発行: Grand View Research, Inc.
ページ情報: 英文 140 Pages
納期: 2-10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の高薬理活性原薬(HPAPI)市場規模は、2028年までに388億4,000万米ドルに達し、2021年から2028年の間に8.4%のCAGRで成長すると予測されています。

市場は、標的療法への注目の高まりと、がん治療の需要の急増により牽引されています。

がんの有病率の上昇は、高薬理活性原薬(HPAPI)市場を牽引すると予想される主な要因です。そして、がん治療にかかる費用は、2020年末までに1,740億米ドルに達すると予想されており、これが市場の成長を加速させると考えられています。

当レポートでは、世界の高薬理活性原薬(HPAPI)市場について調査し、市場の概要・実績・COVID-19の影響、製品別・メーカータイプ別・薬剤タイプ別・用途別・地域別の市場分析、競合情勢、主要企業のプロファイルなどを提供しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 高薬理活性原薬市場:変数、動向および範囲

  • 市場の促進要因分析
  • 普及・成長の見通しマッピング
  • ユーザー視点分析
  • 規制シナリオ
  • 価格分析
  • ジェネリック医薬品が市場全体に与える影響

第4章 高薬理活性原薬市場:セグメント分析、製品別(2017年~2028年)

  • 製品の市場シェア分析(2020年・2028年)
    • 合成
    • バイオテクノロジー

第5章 高薬理活性原薬市場:セグメント分析、メーカータイプ別(2017年~2028年)

  • メーカータイプの市場シェア分析(2020年・2028年)
    • 社内
    • アウトソーシング

第6章 高薬理活性原薬市場:セグメント分析、薬剤タイプ別(2017年~2028年)

  • 薬剤タイプの市場シェア分析(2020年・2028年)
    • イノベーティブ
    • ジェネリック

第7章 高薬理活性原薬市場:セグメント分析、用途別(2017年~2028年)

  • 用途の市場シェア分析(2020年・2028年)
    • 腫瘍
    • ホルモン障害
    • 緑内障
    • その他

第8章 高薬理活性原薬市場:セグメント分析、地域別(2017年~2028年)

  • 地域別の市場シェア分析(2020年・2028年)
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ

第9章 競合情勢

  • 近年の動向・影響分析・主要市場参入企業
    • Ansoff matrix
  • 主要取引・戦略的提携の分析
    • 合弁企業
    • ライセンシング・パートナーシップ
    • 技術協力
  • 企業/競合の分類
  • ベンダー情勢
    • 主要流通業者・チャネルパートナーリスト
    • 主要顧客
  • 公開会社
    • 会社の市況分析
  • 民間企業
    • 主要な新興企業のリスト
    • 地域ネットワークマップ
  • 企業プロファイル
    • BASF SE
    • CordenPharma International
    • Dr. Reddy's Laboratories Ltd.
    • Carbogen Amcis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Albany Molecular Research Inc.
    • Sanofi
    • Merck & Co., Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim GmbH
    • Lonza
    • Cipla Inc.
図表

List of Tables

  • TABLE 1 Estimated new cancer case statistics 2016 & 2018
  • TABLE 2 Global High potency active pharmaceutical ingredients market, by region, 2017 - 2028 (USD Million)
  • TABLE 3 Global High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 4 Global High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 5 Global High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 6 Global High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 7 North America High potency active pharmaceutical ingredients market, by country, 2017 - 2028 (USD Million)
  • TABLE 8 North America High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 9 North America High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 10 North America High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 11 North America High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 12 U.S. High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 13 U.S. High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 14 U.S. High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 15 U.S.High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 16 Canada High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 17 Canada High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 18 Canada High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 19 Canada High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 20 Europe High potency active pharmaceutical ingredients market, 2017 - 2028 (USD Million)
  • TABLE 21 Europe High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 22 Europe High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 23 Europe High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 24 Europe High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 25 U.K. High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 26 U.K. High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 27 U.K. High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 28 U.K. High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 29 Germany High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 30 Germany High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 31 Germany High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 32 Germany High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 33 Spain High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 34 Spain High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 35 Spain High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 36 Spain High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 37 France High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 38 France High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 39 France High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 40 France High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 41 Italy High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 42 Italy High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 43 Italy High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 44 Italy High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 45 Russia High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 46 Russia High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 47 Russia High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 48 Russia High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 49 Switzerland High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 50 Switzerland High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 51 Switzerland High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 52 Switzerland High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 53 Asia Pacific High potency active pharmaceutical ingredients market, 2017 - 2028 (USD Million)
  • TABLE 54 Asia Pacific High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 55 Asia Pacific High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 56 Asia Pacific High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 57 Asia Pacific High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 58 Japan High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 59 Japan High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 60 Japan High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 61 Japan High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 62 China High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 63 China High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 64 China High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 65 China High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 66 India High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 67 India High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 68 India High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 69 India High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 70 Latin America High potency active pharmaceutical ingredients market, 2017 - 2028 (USD Million)
  • TABLE 71 Latin America High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 72 Latin America High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 73 Latin America High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 74 Latin America High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 75 Brazil High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 76 Brazil High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 77 Brazil High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 78 Brazil High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 79 Mexico High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 80 Mexico High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 81 Mexico High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 82 Mexico High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 83 Argentina High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 84 Argentina High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 85 Argentina High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 86 Argentina High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 87 Chile High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 88 Chile High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 89 Chile High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 90 Chile High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 91 Colombia High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 92 Colombia High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 93 Colombia High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 94 Colombia High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 95 MEA High potency active pharmaceutical ingredients market, 2017 - 2028 (USD Million)
  • TABLE 96 MEA High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 97 MEA High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 98 MEA High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 99 MEA High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)
  • TABLE 100 South Africa High potency active pharmaceutical ingredients market, by product, 2017 - 2028 (USD Million)
  • TABLE 101 South Africa High potency active pharmaceutical ingredients market, by drug type, 2017 - 2028 (USD Million)
  • TABLE 102 South Africa High potency active pharmaceutical ingredients market, by manufacturer type, 2017 - 2028 (USD Million)
  • TABLE 103 South Africa High potency active pharmaceutical ingredients market, by application, 2017 - 2028 (USD Million)

List of Figures

  • FIG. 1 High Potency Active Pharmaceutical Ingredients (HPAPIs) market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 QFD modeling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Primary interviews, by sources
  • FIG. 10 Primary interviews, by region
  • FIG. 11 High potency active pharmaceutical ingredients market summary
  • FIG. 12 Market driver relevance analysis (Current & future impact)
  • FIG. 13 Estimated number of cancer cases (5 year) worldwide
  • FIG. 14 New cases of cancer worldwide (2018)
  • FIG. 15 High potency active pharmaceutical ingredients market restraint impact
  • FIG. 16 Penetration and growth prospect mapping
  • FIG. 17 User perspective analysis
  • FIG. 18 SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 19 Porter's five forces analysis
  • FIG. 20 High potency active pharmaceutical ingredients product outlook: key takeaways
  • FIG. 21 High potency active pharmaceutical ingredients market: product movement analysis
  • FIG. 22 Synthetic market, 2017 - 2028 (USD Million)
  • FIG. 23 Biotech market, 2017 - 2028 (USD Million)
  • FIG. 24 High potency active pharmaceutical ingredients market type of manufacturer outlook: Key takeaways
  • FIG. 25 High potency active pharmaceutical ingredients market: type of manufacturer movement analysis
  • FIG. 26 In-house market, 2017 - 2028 (USD Million)
  • FIG. 27 Outsourced market, 2017 - 2028 (USD Million)
  • FIG. 28 High potency active pharmaceutical ingredients market application outlook: key takeaways
  • FIG. 29 High potency active pharmaceutical ingredients market: drug type movement analysis
  • FIG. 30 Innovative market, 2017 - 2028 (USD Million)
  • FIG. 31 Generic market, 2017 - 2028 (USD Million)
  • FIG. 32 High potency active pharmaceutical ingredients market application outlook: key takeaways
  • FIG. 33 High potency active pharmaceutical ingredients market: application movement analysis
  • FIG. 34 Oncology market, 2017 - 2028 (USD Million)
  • FIG. 35 Hormonal disorders market, 2017 - 2028 (USD Million)
  • FIG. 36 Glaucoma market, 2017 - 2028 (USD Million)
  • FIG. 37 Other applications market, 2017 - 2028 (USD Million)
  • FIG. 38 Regional marketplace: key takeaways
  • FIG. 39 Regional outlook, 2020 & 2028
  • FIG. 40 North America
  • FIG. 41 North America. market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 42 U.S.
  • FIG. 43 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 44 Canada
  • FIG. 45 Canada market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 46 Europe
  • FIG. 47 Europe market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 48 U.K.
  • FIG. 49 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 50 Germany
  • FIG. 51 Germany market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 52 France
  • FIG. 53 France market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 54 Spain
  • FIG. 55 Spain market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 56 Italy
  • FIG. 57 Italy market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 58 Russia
  • FIG. 59 Russia market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 60 Switzerland
  • FIG. 61 Switzerland market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 62 Asia Pacific
  • FIG. 63 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 64 Japan
  • FIG. 65 Japan market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 66 China
  • FIG. 67 China market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 68 India
  • FIG. 69 India market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 70 Latin America
  • FIG. 71 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 72 Brazil
  • FIG. 73 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 74 Mexico
  • FIG. 75 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 76 Argentina
  • FIG. 77 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 78 Colombia
  • FIG. 79 Colombia market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 80 Chile
  • FIG. 81 Chile market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 82 Middle East & Africa
  • FIG. 83 MEA market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 84 South Africa
  • FIG. 85 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 86 Ansoff Matrix
  • FIG. 87 Strategy mapping
  • FIG. 88 Company/Competition Categorization
  • FIG. 89 Heat Map Analysis
  • FIG. 90 Regional Network Map
目次
Product Code: 978-1-68038-563-2

High Potency Active Pharmaceutical Ingredients Market Growth & Trends:

The global high potency active pharmaceutical ingredients market size is expected to reach USD 38.84 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.4% from 2021 to 2028. The market is driven by an increased focus on targeted therapies and a surge in demand for cancer therapies.

The rising prevalence of cancer is a major factor expected to drive the market for high potency active pharmaceutical ingredients (HPAPIs). According to the WHO, cancer is the second biggest cause of death, causing over 9.6 million deaths in 2018 and the use of tobacco is responsible for 22% of cancer deaths. As per the CDC, the risk factors such as lifestyle changes including smoking, obesity, alcohol consumption, and exposure to UV radiation from the sun or tanning beds have contributed to the overall burden of the disease. Moreover, the cost of cancer care is anticipated to reach USD 174 billion by the end of 2020, which is anticipated to accelerate the market growth.

Increased demand for antiviral drugs such as remdesivir for COVID-19 treatment is fueling the demand for high potency antiviral HPAPIs. The change in supplier dynamics owing to COVID-19 and the increased focus of governments on pharmaceutical raw materials, such as HPAPIs, are driving the market.

Japan and China are among the leading countries with numerous biotech companies involved in the production of HPAPIs. The presence of major companies such as Takeda and Sankyo has boosted the development of biotechnology-derived APIs in these countries. Furthermore, the growth of the biotech segment can be attributed to the high investments in the biotechnology and biopharmaceutical sectors. This allows the innovation of new molecules that aid in the treatment of diseases, such as cancer.

Key players are leveraging various strategies to increase their production capabilities and promote the outreach of their product offerings. For instance, in July 2020, CordenPharma International announced the expansion of its peptide manufacturing unit in Colorado to address the increased demand for peptide APIs. This expansion will enable the company to grow and help in generating increased revenue.

High Potency Active Pharmaceutical Ingredients Market Report Highlights:

  • In 2020, the synthetic product segment held the largest share of over 70.0% owing to the easy availability of raw materials and highly developed manufacturing systems
  • By manufacturer type, the outsourced segment is projected to grow at the fastest rate over the forecast period
  • Based on drug type, the innovative segment held the largest revenue share in 2020 owing to the increased focus on R&D
  • In terms of application, the oncology segment dominated the HPAPIs market in 2020 owing to the rising incidence of cancer worldwide
  • Asia Pacific is expected to witness the fastest growth during the forecast period due to the improving manufacturing infrastructure and the presence of numerous generic HPAPI manufacturing companies

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
    • 1.2.1 Information procurement
  • 1.3 Information or Data Analysis
  • 1.4 Market Formulation & Validation
  • 1.5 Region-wise Market Calculation
    • 1.5.1 Region-Wise Market: Base Estimates
    • 1.5.2 Global Market: CAGR Calculation
  • 1.6 Region-based Segment Share Calculation
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
    • 1.8.1 Primary interview breakup
      • 1.8.1.1 Data for primary interviews, by sources
      • 1.8.1.2 Data for primary interviews, by region

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 High Potency Active Pharmaceutical Ingredients Market Variables, Trends & Scope

  • 3.1 Market Driver Analysis
    • 3.1.1 Rising prevalence of cancer
    • 3.1.2 Growth of targeted therapies
    • 3.1.3 Increasing application of HPAPIs
    • 3.1.4 Market Restraint Analysis
      • 3.1.4.1 Large investments and very stringent safety and handling specifications associated with the production of HPAPIs
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 User Perspective Analysis
  • 3.4 Regulatory Scenario
  • 3.5 Pricing Analysis
  • 3.6 Impact of generic drugs on the overall market
    • 3.6.1 High Potency Active Pharmaceutical Ingredients - SWOT Analysis, By Factor (political & legal, economic and technological)
    • 3.6.2 Industry Analysis - Porter's

Chapter 4 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Product, 2017 - 2028 (USD Million)

  • 4.1 Product Market Share Analysis, 2020 & 2028
    • 4.1.1 Synthetic
      • 4.1.1.1 Synthetic market estimates and forecasts, 2017 - 2028 (USD Million)
    • 4.1.2 Biotech
      • 4.1.2.1 Biotech market estimates and forecasts, 2017 - 2028 (USD Million)

Chapter 5 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Manufacturer Type, 2017 - 2028 (USD Million)

  • 5.1 Manufacturer Type Market Share Analysis, 2020 & 2028
    • 5.1.1 In-house
      • 5.1.1.1 In-house market estimates and forecasts, 2017 - 2028 (USD Million)
    • 5.1.2 Outsourced
      • 5.1.2.1 Outsourced market estimates and forecasts, 2017 - 2028 (USD Million)

Chapter 6 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Drug Type, 2017 - 2028 (USD Million)

  • 6.1 Drug Type Market Share Analysis, 2020 & 2028
    • 6.1.1 Innovative
      • 6.1.1.1 Innovative market estimates and forecasts, 2017 - 2028 (USD Million)
    • 6.1.2 Generic
      • 6.1.2.1 Generic market estimates and forecasts, 2017 - 2028 (USD Million)

Chapter 7 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Application, 2017 - 2028 (USD Million)

  • 7.1 Application Market Share Analysis, 2020 & 2028
    • 7.1.1 Oncology
      • 7.1.1.1 Oncology market estimates and forecasts, 2017 - 2028 (USD Million)
    • 7.1.2 Hormonal disorders
      • 7.1.2.1 Hormonal disorders market estimates and forecasts, 2017 - 2028 (USD Million)
    • 7.1.3 Glaucoma
      • 7.1.3.1 Glaucoma market estimates and forecasts, 2017 - 2028 (USD Million)
    • 7.1.4 Other Applications
      • 7.1.4.1 Other applications market estimates and forecasts, 2017 - 2028 (USD Million)

Chapter 8 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Region, 2017 - 2028 (USD Million)

  • 8.1 High Potency Active Pharmaceutical Ingredients Market, Market Share by Region, 2020 & 2028
    • 8.1.1 North America
      • 8.1.1.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.1.2 U.S.
      • 8.1.1.2.1 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.1.3 Canada
      • 8.1.1.3.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
    • 8.1.2 Europe
      • 8.1.2.1 Europe market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.2.2 U.K.
      • 8.1.2.2.1 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.2.3 Germany
      • 8.1.2.3.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.2.4 France
      • 8.1.2.4.1 France market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.2.5 Spain
      • 8.1.2.5.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.2.6 Italy
      • 8.1.2.6.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.2.7 Russia
      • 8.1.2.7.1 Russia market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.2.8 Switzerland
      • 8.1.2.8.1 Switzerland market estimates and forecast, 2017 - 2028 (USD Million)
    • 8.1.3 Asia Pacific
      • 8.1.3.1 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.3.2 Japan
      • 8.1.3.2.1 Japan market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.3.3 China
      • 8.1.3.3.1 China market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.3.4 India
      • 8.1.3.4.1 India market estimates and forecast, 2017 - 2028 (USD Million)
    • 8.1.4 Latin America
      • 8.1.4.1 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.4.2 Brazil
      • 8.1.4.2.1 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.4.3 Mexico
      • 8.1.4.3.1 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.4.4 Argentina
      • 8.1.4.4.1 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.4.5 Colombia
      • 8.1.4.5.1 Colombia market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.4.6 Chile
      • 8.1.4.6.1 Chile market estimates and forecast, 2017 - 2028 (USD Million)
    • 8.1.5 Middle East and Africa
    • 8.1.6 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
      • 8.1.6.1 South Africa
      • 8.1.6.1.1 South Africa market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Recent developments & impact analysis, by key market participants
    • 9.1.1 Ansoff matrix
  • 9.2 Major deals & strategic alliances analysis
    • 9.2.1 Joint Ventures
    • 9.2.2 Licensing and Partnerships
    • 9.2.3 Technological Collaborations
  • 9.3 Company/Competition Categorization
  • 9.4 Vendor Landscape
    • 9.4.1 List of key distributors and channel partners
    • 9.4.2 Key customers
  • 9.5 Public Companies
    • 9.5.1 Company market position analysis
  • 9.6 Private Companies
    • 9.6.1 List of key emerging companies
    • 9.6.2 Regional Network Map
  • 9.7 Company Profiles
    • 9.7.1 BASF SE
      • 9.7.1.1 Company Overview
      • 9.7.1.2 Financial Performance
      • 9.7.1.3 Product Benchmarking
      • 9.7.1.4 Strategic Initiatives
    • 9.7.2 CordenPharma International
      • 9.7.2.1 Company Overview
      • 9.7.2.2 Product Benchmarking
      • 9.7.2.3 Strategic Initiatives
    • 9.7.3 Dr. Reddy's Laboratories Ltd.
      • 9.7.3.1 Company Overview
      • 9.7.3.2 Financial Performance
      • 9.7.3.3 Product Benchmarking
      • 9.7.3.4 Strategic Initiatives
    • 9.7.4 Carbogen Amcis AG
      • 9.7.4.1 Company Overview
      • 9.7.4.2 Financial Performance
      • 9.7.4.3 Product Benchmarking
      • 9.7.4.4 Strategic Initiatives
    • 9.7.5 Pfizer Inc.
      • 9.7.5.1 Company Overview
      • 9.7.5.2 Financial Performance
      • 9.7.5.3 Product Benchmarking
      • 9.7.5.4 Strategic Initiatives
    • 9.7.6 Sun Pharmaceutical Industries Ltd.
      • 9.7.6.1 Company Overview
      • 9.7.6.2 Financial Performance
      • 9.7.6.3 Product Benchmarking
      • 9.7.6.4 Strategic Initiatives
    • 9.7.7 Teva Pharmaceutical Industries Ltd.
      • 9.7.7.1 Company Overview
      • 9.7.7.2 Financial Performance
      • 9.7.7.3 Product Benchmarking
      • 9.7.7.4 Strategic Initiatives
    • 9.7.8 Albany Molecular Research Inc.
      • 9.7.8.1 Company Overview
      • 9.7.8.2 Product Benchmarking
      • 9.7.8.3 Strategic Initiatives
    • 9.7.9 Sanofi
      • 9.7.9.1 Company Overview
      • 9.7.9.2 Financial Performance
      • 9.7.9.3 Product Benchmarking
      • 9.7.9.4 Strategic Initiatives
    • 9.7.10 Merck & Co., Inc.
      • 9.7.10.1 Company Overview
      • 9.7.10.2 Financial Performance
      • 9.7.10.3 Product Benchmarking
      • 9.7.10.4 Strategic Initiatives
    • 9.7.11 Novartis AG
      • 9.7.11.1 Company Overview
      • 9.7.11.2 Financial Performance
      • 9.7.11.3 Product Benchmarking
      • 9.7.11.4 Strategic Initiatives
    • 9.7.12 F. Hoffmann-La Roche Ltd.
      • 9.7.12.1 Company Overview
      • 9.7.12.2 Financial Performance
      • 9.7.12.3 Product Benchmarking
      • 9.7.12.4 Strategic Initiatives
    • 9.7.13 Bristol-Myers Squibb Company
      • 9.7.13.1 Company Overview
      • 9.7.13.2 Financial Performance
      • 9.7.13.3 Product Benchmarking
      • 9.7.13.4 Strategic Initiatives
    • 9.7.14 Boehringer Ingelheim GmbH
      • 9.7.14.1 Company Overview
      • 9.7.14.2 Financial Performance
      • 9.7.14.3 Product Benchmarking
      • 9.7.14.4 Strategic Initiatives
    • 9.7.15 Lonza
      • 9.7.15.1 Company Overview
      • 9.7.15.2 Financial Performance
      • 9.7.15.3 Product Benchmarking
      • 9.7.15.4 Strategic Initiatives
    • 9.7.16 Cipla Inc.
      • 9.7.16.1 Company Overview
      • 9.7.16.2 Financial Performance
      • 9.7.16.3 Product Benchmarking
      • 9.7.16.4 Strategic Initiatives